The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Thursday, August 13, 2026

Subject of the day

DHR

Concerning the House

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

United States · www.danaher.com

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$23.88B+4.0%
Gross profit$14.03B+16.1%
Operating income$4.86B+6.6%
Net income$3.61B+6.5%
Cash from ops$6.69B+8.3%
Quotation

$203.89

-1.90 (-0.9%)

52w hi$241.04
52w lo$161.57
Vol1.46M
As ofAug 13
The Verdict

Hold

Our score +0.13

Short-0.09
Medium+0.24
Long+0.34

computed 2026-08-13

By the Numbers

Danaher Corporation

Healthcare · Diagnostics & Research

Market cap$143.33B
Enterprise value$168.19B
Trailing P/E36.28x
Forward P/E21.93x
EV / EBITDA20.95x
P / S (ttm)5.71x
Profit margin15.9%
Return on equity7.6%
Revenue growth+5.5%
Earnings growth+59.7%
Debt / equity52.97
Risk Metrics
Beta vs SPX0.78
Corr SPX0.41
Annual vol30.6%
Annual ret-9.1%
Sharpe-0.30
Max DD-41.8%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.26
Sector+0.12
Technical+0.01
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$207.06$207.49$202.17$203.891.46M
Aug 12$204.55$207.59$202.00$205.793.04M
Aug 11$208.05$208.44$206.09$207.442.47M
Aug 10$203.26$209.37$200.78$209.373.68M
Aug 7$199.40$205.19$198.44$204.763.32M